glp 1 approved for prediabetes GLP-1 Receptor Agonists and Other Drugs GLP-1 Costs Explained: Managing Coverage

This product can be taken any time of the day, with or without food, based on your preference

Also published in the New England Journal of Medicine in 2022, the SURMOUNT-1 trial demonstrated that tirzepatide at the 15 mg dose produced an average weight loss of 22.5% of body weight over 72 weeks approaching results typically seen with bariatric surgery (Jastreboff et al., 2022, PMID: 35658024)

Adjustments in bowel preparation protocols and fasting guidelines may be necessary to ensure optimal visualization and reduce the risk of procedural complications

Comprehensive stool analysis, food-sensitivity panels, and inflammatory markers are frequently ordered alongside the protocol